Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study

This article has no abstract
Epistemonikos ID: 40d57c9fc8566ad392500c6235784f874a77d02c
First added on: Feb 11, 2025